Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

To join this study, you need to have bowel cancer that has been confirmed by a lab test and has spread to other parts of your body. Your doctors also need to know the specific type of your cancer cells (called 'RAS status'). This study is for you if you cannot have stronger chemotherapy treatments or surgery that would completely remove the cancer that has spread. You also shouldn't have had any other cancer drug treatment for your advanced bowel cancer before.

There are also some general health requirements. Your doctors will check that your blood, kidney, liver, and blood clotting functions are all working well enough. You also need to be able to carry out most of your normal daily activities without too much difficulty, as assessed by a score called ECOG performance status of 2 or less. This study is open to both men and women, aged 18 and over.

There are certain reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, or might become pregnant during the study. You also can't have serious symptoms from cancer in your brain or have had major surgery recently (within 4 weeks). If you've had a bad reaction to similar medicines in the past, or if the study medicines (S95005, bevacizumab, capecitabine) have specific warnings or contraindications that apply to you, you wouldn't be able to participate. You also can't be involved in another similar medical study at the same time.

If you decide to take part in this study, you will likely have regular visits to the hospital or clinic. These visits will involve various checks and tests, such as blood tests, scans, and physical examinations, to monitor your health and how well the treatment is working. You will receive one of the two treatment combinations being compared, which will involve taking medication, possibly both as pills and through a drip (infusion).

The exact schedule of visits and tests will be explained to you by the study team, but generally, they will be more frequent at the beginning of the study and might become less frequent over time. The study will continue as long as the treatment is helping you and you are not experiencing significant side effects. There will also be a follow-up period after you finish the treatment to see how you are doing long-term. The total duration of your participation, including follow-up, will vary depending on your individual response to treatment.